HIF1A and metastatic malignant neoplasm: The clinical development of echinomycin (7) was also discontinued due to the lack of anticancer efficacy in patients with solid tumors [330,331,332], but its incorporation in liposomes has been recently suggested as a safe and effective therapeutic option, profiting from the HIF-1α inhibition in metastatic cancers [333].